Wedbush Comments on Allena Pharmaceuticals Inc’s FY2022 Earnings (ALNA)

Allena Pharmaceuticals Inc (NASDAQ:ALNA) – Wedbush issued their FY2022 earnings per share (EPS) estimates for shares of Allena Pharmaceuticals in a report issued on Thursday. Wedbush analyst L. Moussatos expects that the company will post earnings of $2.19 per share for the year. Wedbush has a “Buy” rating on the stock.

Other analysts have also recently issued research reports about the company. Credit Suisse Group assumed coverage on Allena Pharmaceuticals in a research report on Monday, November 27th. They set an “outperform” rating and a $22.00 price target for the company. Jefferies Group assumed coverage on Allena Pharmaceuticals in a research report on Monday, November 27th. They set a “buy” rating and a $22.00 price target for the company. Cowen assumed coverage on Allena Pharmaceuticals in a research report on Monday, November 27th. They set an “outperform” rating for the company. Finally, ValuEngine raised Allena Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Allena Pharmaceuticals has a consensus rating of “Buy” and an average target price of $24.67.

Allena Pharmaceuticals (ALNA) traded down $0.45 during trading on Friday, hitting $6.91. The stock had a trading volume of 46,330 shares, compared to its average volume of 53,426. The company has a quick ratio of 4.83, a current ratio of 4.83 and a debt-to-equity ratio of -0.09. Allena Pharmaceuticals has a 52-week low of $6.88 and a 52-week high of $15.40.

Allena Pharmaceuticals (NASDAQ:ALNA) last posted its quarterly earnings data on Thursday, December 14th. The company reported ($3.49) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($3.11).

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Allena Pharmaceuticals during the 4th quarter worth about $2,281,000. Bank of New York Mellon Corp acquired a new stake in Allena Pharmaceuticals during the 4th quarter worth about $102,000. Finally, Dean Capital Investments Management LLC purchased a new position in shares of Allena Pharmaceuticals during the 4th quarter valued at about $116,000. 0.01% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This news story was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/09/wedbush-comments-on-allena-pharmaceuticals-incs-fy2022-earnings-alna.html.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply